Moxifloxacin: Results of clinical practice

Antibiotiki i Khimioterapiya

Volumn 47, Issue 10, 2002, Pages 32-36

  Yakovlev, V P ^a   Polushkina, N P ^a  

^a A V VISHNEVSKY INSTITUTE OF SURGERY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

BACTERIAL SKIN DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; HUMAN; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; CLINICAL TRIALS; FLUOROQUINOLONES; HUMANS; PNEUMONIA; QUINOLINES; RESPIRATORY TRACT INFECTIONS; SINUSITIS; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 11244319638     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Patel T., Pearl J., Williams J. et al. Efficacy and safety on ten day moxifloxacin 400 mg once daily in the treatment of patients with community-aquired pneumonia. Respir Med 2000; 94: 97-105.
2. Springsklee M. Clinical needs in the millennium - pneumonia - the role of moxifloxacin. 1st Intern. Moxifloxacin Symp./Berlin, 1999, Mandell L. ed. Springer-Verlag; 2000; 154-158.
3. Hoffken G., Meyer H.P., Sprenger K. et al. Efficacy and safety of moxifloxacin (MFX) vs clarithromycin (CLR) for the treatment of community-acquired pneumonia (CAP). 21st Intern Congr Chemother. Birmingham, 1999, Abstr No. P390. J Antimicrob Chemother 1999; 44: Suppl. A.
4. Fogarty C., Grossman C., Williams J. et al. Efficacy and safety of moxifloxacin vs clarithromyin for community-acquired pneumonia. Infect Med 1999; 16: 11: 748-763.
5. Avelox. Moxifloxacin hydrochlorid. Monograph. Bayer, 2000.
6. Lorenz J., Busch W., Thate-Waschke I. M. Moxifloxacin 400 mg once daily for 5 days in patients with AECB: clinical assessment and patient's rating. 3rd Eur Congr Chemother. Madrid. 2000; Abstr No. M173. Spanish J Chemother 2000; 13: Suppl.
7. Wilson R., Kubin R., Ballin I. et al. Five day moxifloxacin compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimiciob Chemother 1999; 44: 501-513.
8. Urueta J., Ariza H., De Brito J. et al. Safety and efficacy of moxifloxacin vs levofloxacin in the treatment of AECB 11th Eur Congr Clin Microbiol Infect Dis. Istanbul, 2001;Abstr: No. P864. Clin. Microbiol. Infect 2001; 7: Supp. 1.
9. Church D. Clinical needs in the millennium - acute exacerbations of chronic bronchitis -the role of moxifloxacin. 1st Intern. Moxifloxacin Symp. Berlin, 1999; Mandell L., ed. Springer-Verlag; 2000; 166-168.
10. Schaberg T. Comparative effect of moxifloxacin and co-amoxiclav in the treatment of AECB. 10th Eur Congr Clin Microbiol Infect Dis. Stockholm, 2000; Abstr; No. WeP 236. Clin Microbiol Infect. 2000; 6: Suppl. 1.
11. Hampel B. Clinical needs in the millennium - rhmosinusitis - the role of moxifloxacin 1st Intern. Moxifloxacin Symp. Berlin, 1999, Mandell L., ed. Springer-Verlag; 2000; 174-177.
12. Burke T., Villanueva C., Mariano H. et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther 1999; 21: 10: 1664-1677.
13. Kiossek J. M., the sinusitis study group. Moxifloxacin versus trovafloxacin in the treatment of acute sinusitis. 3rd Eur Congr Chemother. Madrid, 2000; Abstr: No. M178. Spanish J. Chemother 2000; 13: Suppl. 2.
14. Baz M. N., Jannetti W., Villanaeva C. et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Therapeutic Trends 1999; 17: 4: 303-319.
15. Parish L. C., Heyd A., Haverstock D. et al. Efficacy and safety of moxifloxacin versus cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections. 21st Intern Congr Chemother. Birmingham, 1999; Abstr: No. P441. J Antimicrob Chemother 1999; 44: Suppl. A.
16. Del Rosal P. L., Martinez R., Fabian G. et al. Efficacy and safety of moxifloxacin vs cephalexin in the treatment mild to moderate uncomplicated skin and sof tissue infections (USSSI). Ibid. Abstr. No. P493.
17. Heystek M. J., Tellarini M., Schmitz H. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease. Ibid. Abstr No. P466.
18. Ball P. Fluoroquinolone safety and tolerability. 1st Intern Moxifloxacin Symp. Berlin, 1999, Mandell L., ed. Springer-Verlag; 2000; 138-143.
19. Springsklee M., Reiter C., Meyer J. Safety and tolerability profile of moxifloxacin (MXF). Eur Congr Clin Microbiol Infect Dis 1999; Posters: No. Po208.
20. Kubin R., Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. 40th Intersci Conf Antimicrob Agents Chemother. Toronto, 2000; Abstr: No. 820.